Crispr Therapeutics Ag (CRSP)

EBITDA Margin

-3390.20%

TTM · Period ending:

CRSP logo

CRSP EBITDA Margin

Latest reported-3390.20%
CRSP TTM EBITDA Margin (-10341.70% → -3390.20%)
High-resolution chart · PNG

CRSP ebitda margin history

Trailing twelve months (TTM). Each value covers four complete reported quarters.

Crispr Therapeutics Ag EBITDA Margin — Trailing twelve months (TTM)
Period endingEBITDA Margin
-3,390.2031%
-13,309.9683%
-15,911.2821%
-1,237.6268%
-1,190.7572%
-980.2158%
-937.6785%
-107.7045%
-121.2038%
-72.1708%
-35.3743%
-199.74%
-236.8377%
-502.1564%
-143,653.211%
-4,837.9999%
-4,402.6467%
37.4661%
43.7851%
47.4501%
51.0515%
-50,469.1099%
-48,018.2197%
-294.2429%
0.9922%
9.5298%
17.7717%
-5.6355%
-15,179.8338%
-8,768.7202%
-5,191.3252%
-309.5121%
-224.9637%
-170.9145%
-150.3134%
-783.406%
-766.0739%
-1,006.1426%
-1,278.6987%
-1,799.5435%
-3,089.3281%
-4,635.408%
-10,341.7004%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.